

CURRICULUM VITAE

DAVID G. MORGAN, PH.D.

1 JAN 2014

EDUCATION

<u>Degree</u>		<u>Year</u>	<u>Field</u>
Northwestern University	B.A.	1974	Philosophy/Psychology
Northwestern University	M.S.	1978	Neurobiology
Northwestern University	Ph.D.	1981	Neurobiology

PROFESSIONAL EXPERIENCE

TEACHING ASSISTANT:	Northwestern University; 1976
INSTRUCTOR:	Northwestern University, 6 Semesters; 1976-1980
POSTDOCTORAL FELLOW:	University of Southern California, Andrus Gerontology Center Neurobiology Section; 1981 - 1984
RESEARCH ASSOCIATE:	University of Southern California, Andrus Gerontology Center, 1984 - 1986
VISITING SCIENTIST:	University of Umea, Sweden, Department of Pathology, Summer, 1984
RESEARCH ASST. PROFESSOR:	University of Southern California, Department of Biological Sciences; 1986 - 1988
ASSISTANT PROFESSOR:	University of Southern California, School of Gerontology; Joint Appointment in Dept. of Biological Sciences: 1988 - 1992
ASSOCIATE PROFESSOR:	University of South Florida, College of Medicine, Dept. of Pharmacology: 1992 -1998
ASSOCIATE DIRECTOR:	University of South Florida, Institute on Aging. 1997-2003
PROFESSOR	University of South Florida, Dept. of Pharmacology (now, Molecular Pharmacology and Physiology) 1998-present
DISTINGUISHED PROFESSOR.	USF Health. 2010-present
DIRECTOR	Basic Neuroscience Research, USF College of Medicine 2006-2012
CHIEF SCIENTIFIC OFFICER	USF Health Byrd Alzheimer's Institute, 2009- 2012
CHIEF EXECUTIVE OFFICER	USF Health Byrd Alzheimer's Institute, 2010-present

AWARDS

New Investigator Award in the Neurosciences: American Geriatrics Society, 1985
Nathan Shock New Investigator Award: Gerontological Society of America, 1986
The Anna Greenwall Award: American Federation for Aging Research, 1987
Established Investigator Award: American Heart Association, 1989
USF President's Award for Faculty Excellence, 2002
Distinguished Professor, USF Health, 2010
Notable Alumnus, Northwestern University Neuroscience Program, 2010

Medical Hero Award, Temple Terrace Chamber of Commerce, 2012

ACTIVE SUPPORT

Immunotherapy against tauopathy in a transgenic mouse model R01 NS076308 05/15/2011 – 02/29/2016 Morgan is PI. \$1.75 million total costs, \$340,000 present year
Ketogenesis and Alzheimer Pathology. Alzheimer's Association. 1 AUG 2010 to 30 JUL 2013. Morgan is PI. \$210,000 total, \$70,000 in current year.
Transgenic Mice, Inflammation and the Alzheimer Phenotype. NIA R01 AG15490 5-98 to 4-13, Morgan is Co-PI; M. Gordon, PI, \$1.5 million total costs; \$307,000 current year).
Histone deacetylase-6 inhibition as a treatment for tauopathy. Thome Foundation. 1 JAN 2012 to 31 DEC 2014. Morgan is PI. \$200,000 total.
IVIG in a Mouse Model of Amyloid Deposition. Baxter Inc. 1 Jun 2012 – 31 May 2013 \$100,000 total Benjamin Foundation Endowment. Provides annual stipend and research support for the Benjamin Scholar in Alzheimer's Disease (PhD student) in my laboratory. PI. (\$26,000 annually).

PAST SUPPORT

University Fellowship: Northwestern University, Tuition and Stipend; 1975 - 1978
Postdoctoral Fellowship: Glenn Foundation for Medical Research; 1981
Postdoctoral Fellowship: National Institute of Health Training Grant; 1982 - 1985
Potamkin-Lerner Fellowship in the Neurosciences: The Orentreich Foundation; 1983 - 1985
Visiting Scientist Travel Award: Umea University Hospital, Sweden, 1984
Neuronal Gene Expression in Aging and Stress-Impaired Memory Function: Bus. Inst. on Aging, 1985
Molecular Genetic Approaches to Alzheimer's Disease: The French Foundation, 1985 - 1988
Gene Expression in Alzheimer's Disease: The American Federation for Aging Research, 1987-1990
The Neurotoxicity of Psychomotor Stimulants. Biomedical Research Support Grant, USC, 1987-1988.
Astrocytes in Recovery of Function. Interaction with Aging: American Heart Association, 1989-1994.
Astrocytes in Aging. Neurochemistry, Anatomy and RNA. R01 Grant, NIA. 5-89 through 4-93.
Development of Astrocyte-Specific Brain Lesions: American Heart Association. 1989-1991.
Cellular and Molecular Bases of D2 Declines with Age: Morgan project P01 Grant, NIA, 6-91 to 6-94.
A β Amyloid in Rat Brain. Co-infusion of Defined Plaque Components: Alz. Assn. 7-93 to 6-96.
Formation of Amyloid in Rat Brain by Variants of the A β Peptide. Cephalon Inc. 12-94 to 8-95
The Formation of A β Amyloid Plaques in Aged Rat Brain. Pfizer Inc. 4-95 to 3-96
Regulation and Function of the Presenilins in Brain. Morgan project P01 Grant, NIA 9-96 to 9-99.
Development of a Rat In Vivo A β Fibrillogenesis Model. Pfizer Inc. 4-97 to 12-98
Dietary Antioxidants and Amyloid Pathology in Transgenic Mice. USDA 6-99 to 6-02. PI
MRI Hyperintensity Detection in Aged Brain. NIA R43 AG-18223. 2-01 to 1-02 Co-PI. (K. Gosche, PI)
Anti A β Immunity Against Alzheimer's Disease. NIA R01 AG-20227 15 AUG 01 to 30 JUL 04 Co-PI (K. Ugen P.I.)
A Vaccine Approach to Parkinsons Disease. NINDS R21 NS 43661 1 FEB 02 to 31 JAN 05 PI (\$325,000)
Behavioral and Pathological Analysis of Transgenic Mice. AstraZeneca 1-00 to 3-05. PI (\$140,000)
Evaluation of PCL-016 in transgenic mice. Novactyl Inc. 1 AUG 04 - 31 MAR 05, PI. (\$42,700)
Anti-Amyloid Gene Therapy for AD. Byrd Alzheimer's Center, JUL 04 - JUN 06, PI (\$174,000)
Testing of Compound A. AstraZeneca 1 JAN 06 to 31 DEC 07. Morgan PI. \$114,000
CD40 Modulation of A-beta Vaccine Immune Response. NINDS R01 NS 48335 25 SEP 04 to 31 MAY 08. Morgan Co-PI; J. Tan is PI. \$1.1 million total costs;
Role of CBAT cells in Alzheimer Pathology. Ethicon/Johnson and Johnson. 1 JAN 08 31 DEC 08
AAV Gene Therapy for Alzheimer's Disease, NIA R01 AG 25509, PI. 15 AUG 05 - 30 JUN 11

Curriculum Vitae, David G. Morgan

\$2.2 mill total).

Digital Microscopic Image Scanning System. S10 Equipment Grant, NIH SEP 2009 – AUG 2010, PI

Functional Consequences of Vaccination in AD Tg Mice. NIA R01 AG 18478. 15 SEP-00 to 1 FEB-12

Morgan is P.I. (\$4.3 million total costs;).

Multiple Glial Activation States in Aging Brain, Project 3. NIA P01 AG04418, 1 SEP 06 to 30 JUN 12,

Morgan project (\$1 million total costs; \$200,000 current year). P. Bickford, PI on entire Program. 17 NIH funded grants (78 funded-years)

EDITORIAL/REVIEW BOARDS

*Member, NIH Interventional Testing Program Review Committee
National Research Board, American Federation for Aging Research
Scientific Review Board, Institute for the Study of Aging
Behavioral Neuroscience
Brain Aging
Current Alzheimer's Research
Journal of Neuroimmune Pharmacology
Chinese Journal of Contemporary Neurology and Neurosurgery*

PATENTS ISSUED

Monocytes as a Gene Delivery Vector for Secreted Proteins to Treat Alzheimer's
Patent No. 8,518,391 on August 27, 2013

Curriculum Vitae, David G. Morgan

PUBLICATIONS. Using a recently developed index (h factor) of lifetime scientific impact, Morgan is a 50 using Google Scholar (author on 50 publications with more than 50 citations). Citation # in parentheses at end of selected references.

- 1) **Morgan, D.G.** and A. Routtenberg (1979) Incorporation of intra-striatally injected [3H]fucose into electrophoretically separated glycoproteins. I. Turnover and molecular weight estimations. Brain Research, 179: 329-341.
- 2) **Morgan, D.G.** and A. Routtenberg (1979) Incorporation of intra-striatally injected [3H]fucose into electrophoretically separated glycoproteins. II. The influence of passive avoidance training. Brain Research, 179: 342-354.
- 3) **Morgan, D.G.** and A. Routtenberg (1980) Evidence that a 41,000 dalton brain phosphoprotein is pyruvate dehydrogenase. Biochemical and Biophysical Research Communications, 95: 569-576.
- 4) Mitrius, J.C., **D.G. Morgan**, and A. Routtenberg (1981) In vivo phosphorylation following [32P]orthophosphate injections into neostriatum or hippocampus. Brain Research, 212: 67-81.
- 5) **Morgan, D.G.** and A. Routtenberg (1981) Brain pyruvate dehydrogenase phosphorylation and enzyme activity altered by a training experience. Science, 214: 470-471. (58)
- 6) Routtenberg, A., **D.G. Morgan**, R.G. Conway, M.J. Schmidt, and B. Ghetti (1981) Human brain phosphorylation in vitro. Cyclic AMP stimulation of electrophoretically separated substrates. Brain Research, 222: 323-333.
- 7) **Morgan, D.G.** and A. Routtenberg (1982) Brain pyruvate dehydrogenase activity. Regulation by phosphorylation-dephosphorylation. Brain Research, 251: 391-394.
- 8) Joseph, J.A., R.T. Bartus, D. Clody, **D.G. Morgan**, C.E. Finch, B. Beer, and S. Sesack (1983) Psychomotor performance in the senescent rodent: Reduction of deficits via striatal dopamine receptor up-regulation. Neurobiology of Aging, 4: 313-319.
- 9) **Morgan, D.G.**, J.A. Severson, J.O. Marcusson, and C.E. Finch (1984) Aging and the serotonergic synapse in human brain: A preliminary report. In, Comparative Pathobiology of Major Age Diseases. D. Scarpelli, Ed. Alan R. Liss, New York. pp. 401-410.
- 10) **Morgan, D.G.**, Y.N. Sinha, and C.E. Finch (1984) Chronic domperidone fails to increase striatal spiperone binding sites despite hyperprolactinemia: Comparison with chronic haloperidol. Neuroendocrinology, 38: 407-411.
- 11) **Morgan, D.G.**, J.O. Marcusson, and C.E. Finch (1984) Contamination of serotonin-2 binding sites by an alpha-1 adrenergic component in assays with [³H]spiperone. Life Sciences, 34: 2507-2514. (36)
- 12) Marcusson, J.O., **D.G. Morgan**, B. Winblad, and C.E. Finch (1984) Serotonin receptors in

Curriculum Vitae, David G. Morgan

- aging human brain. Selective reduction of S-2A receptors in frontal cortex and hippocampus. Brain Research, **311** (1984) 51-57. (106)
- 13) **Morgan, D.G.**, C.V. Mobbs, C.A. Anderson, Y.N. Sinha, and C.E. Finch (1985) Hyperprolactinemia fails to increase striatal dopamine receptors in C57BL/6J mice. European Journal of Pharmacology, **107**: 101-104.
 - 14) Rogers, J., W.J. Shoemaker, **D.G. Morgan**, and C.E. Finch (1985) Senescent change in tissue weight and immunoreactive beta-endorphin, enkephalin, and vasopressin in eight regions of C57BL/6J mouse brain and pituitary. Neurobiology of Aging, **6**: 1-9.
 - 15) Marcusson, J., L. Ljung, C. Finch, **D. Morgan**, J. Severson, and B. Winblad (1985) Receptor studies in aging and senile dementia. In: Normal Aging, Alzheimer's Disease and Senile Dementia. Aspects on Etiology, Pathogenesis, Diagnosis and Treatment. C.G. Gottfries (ed.). Editions Univ. Bruxelles (Brussels). pp. 151-155.
 - 16) May, P.C., **D.G. Morgan**, and C.E. Finch (1986) Regional serotonin receptor studies: Chronic methysergide treatment induces a selective and dose-dependent decrease in serotonin-2 receptors in mouse cerebral cortex. Life Sciences, **38**: 1741-1747.
 - 17) **Morgan, D.G.** and C.E. Finch (1986) [³H]Fluphenazine binding to brain membranes. Simultaneous measurement of D-1 and D-2 dopamine receptor sites. Journal of Neurochemistry, **46**: 1623-1631.
 - 18) Johnson, S.A., **D.G. Morgan**, and C.E. Finch (1986). Extensive postmortem stability of RNA from rat and human brain. Journal of Neuroscience Research, **16**: 267-280. (192)
 - 19) Ruth, R.E. and **D.G. Morgan** (1986). Dietary pyridoxine and the susceptibility to limbic motor seizures in rats. Experimental Neurology, **94**: 441-448.
 - 20) **Morgan, D.G.**, P.C. May, and C.E. Finch (1987). Dopamine and serotonin systems in human and rodent brain. Effects of age and neurodegenerative disease. Journal of the American Geriatrics Society **35**:334-345. (127)
 - 21) Osterburg, H.H., N.A. Telford, **D.G. Morgan**, I. Cohen-Becker, P.M. Wise, and C.E. Finch (1987). Hypothalamic monoamines and their catabolites in relation to the estradiol-induced LH surge. Brain Research **409**:31-40.
 - 22) **Morgan, D.G.**, J.O. Marcusson, P. Nyberg, P. Wester, B. Winblad, M.N. Gordon and C.E. Finch (1987). Divergent changes in D-1 and D-2 dopamine binding sites in human basal ganglia during normal aging. Neurobiology of Aging. **8**:195-201. (69)
 - 23) **Morgan, D.G.**, J.S. Randall, N.A. Telford, M.N. Gordon, Y.N. Sinha, C.E. Finch, and P.K. Randall (1987). Genotypic influences on pituitary responsiveness to haloperidol in mice. Psychoneuroendocrinology **12**:211-218.

Curriculum Vitae, David G. Morgan

- 24) **Morgan, D.G.** (1987). The dopamine and serotonin systems during aging in human and rodent brain. A brief review. Progress in Neuropsychopharmacology and Biological Psychiatry 11:153-157. (38)
- 25) May, P.C., H.H. Osterburg, R.J. Mandel, D.G. Morgan, P.K. Randall, and C.E. Finch (1987). Alteration of calmodulin distribution does not accompany dopaminergic supersensitization of the mouse striatum. J. Neurosci. Res. 17:247-250.
- 26) Finch, C.E. and **D.G. Morgan** (1987) Aging and Schizophrenia: A hypothesis relating asynchrony in neural aging processes to the manifestations of schizophrenia and other neurologic diseases with age. In: Schizophrenia and Aging, N. Miller and G.N. Cohen (eds.), Guilford Publications, New York, pp97-108.
- 27) Finch, C., S. Johnson, S. Kohama, S. Lerner, J. Masters, P. May, **D. Morgan**, N. Nichols, G. Pasinetti, and N. Telford (1987) Physiological approaches to the roles of gene regulation in the brain during aging. In Molecular Pathology of Aging, P. Davies and C.E. Finch (eds), Banbury Report 27, Cold Spring Harbor Laboratory, NY, pp 143-148.
- 28) **Morgan, D.G.** Neurotransmitter receptors in Alzheimer's Disease and nonpathological aging (1987) In Molecular Pathology of Aging, P. Davies and C.E. Finch (eds), Banbury Report 27, Cold Spring Harbor Laboratory, NY, pp 21-36.
- 29) **Morgan, D.G.** and C.E. Finch (1988) Dopaminergic changes in the basal ganglia. A generalized phenomenon of aging in mammals. In Central Determinants of Age-Related Declines in Motor Function, J.A Joseph (ed), Annals New York Academy of Science, 515:145-160. (73)
- 30) **Morgan, D.G.**, P.C. May, and C.E. Finch (1988) Neurotransmitter receptors in normal human aging and Alzheimer's disease. In, Receptors and Ligands in Neurological Disorders, A.K. Sen and T.Y. Lee (eds.), Cambridge University Press, Cambridge, England, pp120-147.
- 31) May, P.C., **D.G. Morgan**, D. Salo, J.R. Goss and C.E. Finch (1988) Effects of radioligand oxidation and ascorbate produced lipid peroxidation on serotonin-1 receptor assay: Use of ascorbate and EDTA buffers to prevent [³H]5-HT binding artifacts. J. Neurosci. Res 20:257-262.
- 32) **Morgan, D.G.**, and M.N. Gordon (1988) New approaches to the study of central nervous system function. Immune-nervous system interactions and cell culture. Neurobiol. Aging 9:763-765.
- 33) Finch, C.E., J.R. Goss, S.A. Johnson, S.G. Kohama, P.C. May, J.N. Masters, S.L. Millar, D.G. **Morgan**, N.R. Nichols, H.H. Osterburg and G.M. Pasinetti (1989). Aging and gene expression in mammalian brain: Normal and pathological changes. In Parkinsonism and Aging, D. Calne et al (eds), Raven Press, New York, pp107-113.
- 34) Pasinetti, G., S. Lerner, S.A. Johnson, **D.G. Morgan**, and C.E. Finch (1989). Chronic lesions differentially decrease messenger RNA in dopaminergic neurons of the rat substantia nigra.

Curriculum Vitae, David G. Morgan

Molec. Brain Res. 5:203-209 (54)

- 35) Pasinetti, G.M., **D.G. Morgan**, S.A. Johnson, S.P. Lerner, M.M. Myers, J. Poirier and C.E. Finch (1989). In situ hybridization with immunocytochemistry: An approach to the pharmacology of tyrosine hydroxylase gene expression. Pharmacol. Res. 21:299-311.
- 36) **Morgan, D.G.** (1989) Considerations in the treatment of neurological disorders with trophic factors. Neurobiol. Aging 10:547-548.
- 37) **Morgan, D.G.** and P.C. May (1990). Age-related changes in synaptic neurochemistry; 1983-1988. In Handbook of the Biology of Aging, 3rd Edition, E.L. Schneider and J. Rowe (eds.), Academic Press, Orlando, pp 219-254.
- 38) Finch, C.E. and **D.G. Morgan** (1990). RNA and protein metabolism in the aging brain. In Annual Review of Neuroscience 13:75-87. (76)
- 39) Goss, J.R., C.E. Finch and **D.G. Morgan** (1990). GFAP RNA increases during a wasting state in old mice. Exp. Neurol. 108:266-268.
- 40). Pasinetti, G.M., **D.G. Morgan**, S.A. Johnson, S.L. Millar, and C.E. Finch (1990). Tyrosine hydroxylase mRNA concentration in midbrain dopaminergic neurons is differentially regulated by reserpine. J. Neurochem. 55:1793-1799. (47)
- 41) Goss, J.R., C.E. Finch and **D.G. Morgan** (1991). Age-related changes in glial fibrillary acidic protein RNA in the mouse brain. Neurobiol. Aging 12:165-170. (120)
- 42) Goss, J.R., A.B. Kelly, S.A. Johnson and **D.G. Morgan** (1991). Haloperidol treatment increases D-2 dopamine receptor protein independent of RNA levels in mice. Life Sci. 48:1015-1022.
- 43). **Morgan, D.G.**, C.E. Finch and S.A. Johnson (1991). RNA metabolism in Alzheimer's disease: Selective increase in GFAP RNA. In Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies, K. Iqbal, D.R.C. McLachlan, B. Winblad and H.M. Wisniewski (eds), John Wiley and Sons, New York, pp407-416.
- 44) Pasinetti, G.M. **D.G. Morgan** and C.E. Finch (1991). Transneuronal degeneration of nigral neurons containing GAD mRNA and tyrosine hydroxylase following striatal ibotenic acid lesions. Exp. Neurol. 112:131-139.
- 45). **Morgan, D.G.** and J.A. Walsh (1991). Lectures on the Biology of Aging. The Basics of Aging and Longevity for the Nonscientist. Better Times Publishing, Los Angeles.
- 46) **Morgan, D.G.** (1992) Neurochemical changes with aging. Predisposition towards age-related mental disorders. In Handbook of Mental Health and Aging, 2nd Edition, J.E. Birren (Ed), Academic Press, San Diego, pp175-199.
- 47) **Morgan, D.G.** (1991) Clinical and biochemical aspects of depressive disorders: Serotonin.

Curriculum Vitae, David G. Morgan

Synapse 9:261-271.

- 48) Pasinetti, G.M., H.H. Osterburg, A.B. Kelly, S. Kohama, **D.G. Morgan**, J.F. Reinhard, R.H. Stellwagen and C.E. Finch (1992). Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging. Molecular Brain Research 13:63-73. (53)
- 49) Pasinetti, G.M., S.A Johnson, I. Rozovsky, M. Lampert-Etchells, **D.G. Morgan**, M.N. Gordon, T.E. Morgan, D. Willoughby and C.E. Finch (1992). Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Experimental Neurology 118:117-125. (98)
- 50). Randerath, K., K.L. Putnam, H.H. Osterburg, S.A. Johnson, **D.G. Morgan** and C.E. Finch (1992). Age-dependent increases of DNA adducts (I-compounds) in human and rat brain DNA. Mutation Research 295:11-18. (46)
- 51) Goss, J.R. and **D.G. Morgan** (1993). The effects of age on glial fibrillary acidic protein RNA induction by fimbria/fornix transection in the mouse brain. AGE 16:15-22 (57)
- 52) Pasinetti, G.M., H.W. Cheng, **D.G. Morgan**, M. Lampert-Etchells, T.H. McNeill and C. E. Finch. (1993). Astrocytic messenger RNA responses to striatal deafferentation in male rats. Neuroscience 53:199-211. (38)
- 53) Snow, A.D., R. Sekiguchi, D. Nochlin, K. Kimata, A. Mizutami, M. Arai, W.A. Schreier and D. G. **Morgan** (1994). An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar A β -amyloid in rat brain. Neuron 12:219-234. (263)
- 54) Goss, J.R. and **D.G. Morgan**. (1995) Increased reactivity of glial fibrillary acidic protein following brain injury in aged mice. Journal of Neurochemistry 64:1351-1360.
- 55) Yu, Z.J., **D.G. Morgan** and L. Wecker (1996) Distribution of three nicotinic receptor α 4 mRNA transcripts in the rat brain: Selective regulation by nicotine administration. Journal of Neurochemistry 66:1326-1329.
- 56) **Morgan, D.G.** and M.N. Gordon (1996). Aging and molecular biology. In *The Nobel Symposium on Lifespan Development of Individuals*, D. Magnusson (ed), Cambridge University Press, New York, pp468-487.
- 57) Duff, K., C. Eckman, C. Zehr, X. Yu, C-M. Prada, J. Perez-tur, M. Hutton, L. Buee, Y. Harigaya, **D. Morgan**, M. Gordon, L. Holcomb, L. Refolo, B. Zenk, J. Hardy & S. Younkin (1996). Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710-713. (1218)
- 58) Benkovic, S.A., E. McGowan, N.J. Rothwell, **D.G. Morgan** and M.N. Gordon (1997). Regional and cellular localization of presenilin-2 RNA in rat and human brain. Experimental Neurology

Curriculum Vitae, David G. Morgan

145:555-564

- 59) Gordon, M.N., W.A. Schreier, X. Ou, L.A. Holcomb and **D.G. Morgan**. (1997) Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. Journal of Comparative Neurology 388:106-119. (73)
- 60) Holcomb, L.A., M.N. Gordon, E. McGowan, S. Benkovic, P. Jantzen, K. Wright, I. Saad, R. Mueller, **D. Morgan***, X. Yu, S. Sanders, C. Zehr, K. O=Campo, J. Hardy, C-M. Prada, C. Eckman, S. Younkin, K. Hsiao, K. Duff. (1998) Accelerated Alzheimer-phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Medicine 4:97-101. * corresponding author (868)
- 61) **Morgan, D.**, L. Holcomb, I. Saad, M. Gordon and M. Maines (1998). Impaired spatial navigation learning in transgenic mice over-expressing heme oxygenase-1. Brain Research, 808:110-112.
- 62) Gordon, M.N. C.D Mueller, K.A. Sherman, **D.G. Morgan**, A. Azarro, G. Bobotas and L. Wecker (1999). Oral versus transdermal selegiline: Antidepressant-like activity in rats. Pharmacology, Biochemistry and Behavior, 63:501-506
- 63) Pennypacker, K. R., Hernandez, H, Benkovic, S., **Morgan, D. G.**, Willing, A. E. and Sanberg, P. R. (1999). Induction of presenilins in the rat brain after middle cerebral arterial occlusion. Brain Research Bulletin 48:539-543.
- 64) Holcomb, L.A., M.N. Gordon, P. Jantzen, K. Hsiao, K. Duff and **D. Morgan** (1999). Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits Behavior Genetics, 29:177-185 (236)
- 65) K.A. Wright, **D.G. Morgan**, X. Yu, J.R. Goss, J.M. Salbaum, K. Duff and M.N. Gordon (1999). Mice transgenic for a human amyloid precursor protein promoter-*lacZ* reporter construct: Appropriate cell type expression but not regulation in brain. J. Molecular Neurosci., 13:111-120.
- 66) Holcomb, L.A., M.N. Gordon, S.A. Benkovic and **D.G. Morgan** (2000). A β and perlecan in rat brain. Glial activation, gradual clearance and limited neurotoxicity. Mechanisms Ageing and Development, 112:135-152.
- 67) **Morgan,D**, (2000). The intersection of Alzheimer's disease and typical aging. Neurobiology of Aging 21:159-161
- 68) Jaffar, S. , S.E. Counts, S.Y. Ma, E. Dadko, M.N. Gordon, **D. Morgan** and E.J. Mufson. (2000). Neuropathologic alterations in mutant APP^{swe} and PS1^{m146l} and doubly transgenic mice: a selective increase in p75^{ntr}-containing basal forebrain neurons. Experimental Neurology, 170:227-243. (70)
- 69) **Morgan, D.**, D.M. Diamond, P. Gottschall, K.E. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Hatcher, M. Gordon and G.W. Arendash (2000). Vaccination with A β Peptide Prevents Memory Deficits in an Animal Model of Alzheimer=s

Curriculum Vitae, David G. Morgan

- Disease. Nature 408:982-985. (1260)
- 70). Gordon, M. N., King, D. L., Diamond, D. M., Jantzen, P. T., Boyett, K. L., Hope, C. E., Hatcher, J. M., DiCarlo, G., Gottschall, P., **Morgan, D.** & Arendash, G. W. (2001). Correlation between cognitive deficits and A β deposits in transgenic APP+PS1 mice. Neurobiology of Aging 22:377-385 (152)
- 71). Nilsson, L.N.G., K.R.Bales, G. DiCarlo, M.N. Gordon, **D. Morgan** , S.M. Paul & H. Potter (2001). Alpha-1-antichymotrypsin promotes β -sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. Journal of Neuroscience 21: 1444-1451 (102)
- 72). Arendash, G. W., King, D. L., Gordon, M. N., **Morgan, D.**, Hatcher, J. M., Hope, C. E. & Diamond, D. M. (2001) Progressive behavioral impairments in transgenic mice carrying both mutant APP and PS1 transgenes. Brain Research 891:45-53 (204)
- 73). Arendash, G.W., M.N. Gordon, D.M. Diamond, J.M. Hatcher, L.A. Austin, P. Jantzen, D. DiCarlo, D. Wilcock and **D. Morgan** (2001). Behavioral Assessment of Alzheimer's Transgenic Mice Following Long-Term A β Vaccination: Task Specificity and Correlations between A β Deposition and Spatial Memory. DNA and Cell Biology 20:737-744. (99)
- 74). Dickey, C.A., **D.G. Morgan**, M.N. Gordon and K.E. Ugen (2001). Duration and specificity of the humoral responses in mice vaccinated with the Alzheimer's disease associated amyloid β 1-42 peptide. DNA and Cell Biology 20:723-730. (46)
- 75). DiCarlo, G., D. Wilcock, D. Henderson, M. Gordon, and **D. Morgan** (2001). Intrahippocampal LPS injections reduce A β load in APP+PS1 transgenic mice. Neurobiology of Aging 22: 1007-1012. (117)
- 76). Wilcock, D.M., M.N. Gordon, K.E Ugen, P.E. Gottschall, G. DiCarlo, C. Dickey, K.W. Boyett, P.T. Jantzen, K.E. Connor, J. Melachrinou, J. Hardy and **D. Morgan** (2001). Number of A β inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation and congophilic plaque levels. DNA and Cell Biology 20:731-736 (87)
- 77). Gordon, M.N., and **D.G. Morgan** (2001). Transgenic mice, inflammation and the Alzheimer phenotype. In *Inflammatory Events in Neurodegeneration*, S.C Bondy and A. Campbell (eds), Prominent Press, pp 98-118.
- 78). Gordon, M.N., L.A. Holcomb, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Melachrinou, J. O'Callaghan and **D. Morgan** (2002). Time course of the development of Alzheimer-like pathology in the doubly transgenic mPS1+mAPP mouse. Experimental Neurology 173:183-195 (135)
- 79). **Morgan, D.**, and R.K. Keller (2002) What evidence would prove the amyloid hypothesis? Towards rational drug treatments for Alzheimer's disease. Journal of Alzheimer's Disease 3:257-260

Curriculum Vitae, David G. Morgan

- 80). Jantzen, P.T., K.E. Connor, G. DiCarlo, G.L. Wenk, J.L. Wallace, A.M. Rojiani, D. Coppola, **D. Morgan**, and Marcia N. Gordon (2002). Microglial Activation and A β Deposit Reduction Caused by a Nitric Oxide Releasing NSAID, NCX-2216, in APP+PS1 Transgenic Mice. Journal of Neuroscience 22:2246-2254. (291)
- 81) Ugen, K.E., C. Cao, C. Dickey, D. Wilcock, Y. Bai, M.N. Gordon and **D. Morgan** (2003). Characterization of amyloid beta vaccination strategies in mice. In *Immunization against Alzheimer's Disease and Other Neurodegenerative Disorders*. Springer-Verlag, Berlin, pp21-32
- 82) **Morgan, D** and M.N. Gordon (2003). The amyloid hypothesis of cognitive decline. In Neuroinflammation: Mechanisms and Management 2nd Edn., P. Wood (ed.), Humana Press, pp283-294.
- 83) **Morgan, D.** (2003) Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochemical Research:28:1029-1034. (37)
- 84) **Morgan, D.**, P. Jantzen, D. Wilcock, G. DiCarlo, K. Ugen and M. Gordon (2003) The association of microglial activation and amyloid reduction in APP+PS1 transgenic mice. Current Medicinal Chemistry- Immunologic, Endocrinologic and Metabolic Agents 3:233-243
- 85) Austin, L.A., G.W. Arendash, M.N. Gordon, D.M. Diamond, G. DiCarlo, C. Dickey, K. Ugen, **D. Morgan** (2003) Short-term A β vaccines do not improve cognitive performance in cognitively impaired APP+PS1 mice. Behavioral Neuroscience 117:478-484
- 86) **Morgan, D** (2003) Antibody therapy for Alzheimer's disease. Expert Review of Vaccines 2: 89-95.
- 87) Wilcock, D., G. DiCarlo, D. Henderson, J. Jackson, K. Clarke, K.E. Ugen, M.N. Gordon and **D. Morgan** (2003). Intracranially administered Anti-A β antibodies reduce β -amyloid deposition by mechanisms both independent of and associated with microglial activation. Journal of Neuroscience 23:3745-3751. (209)
- 88) Kassed, C.A., T.L. Butler, M.T. Navidomskis, M.N. Gordon, **D. Morgan**, and K.R. Pennypacker (2003). Mice expressing human mutant presenilin-1 exhibit decreased activation of NF- κ B p50 in hippocampal neurons after injury. Molecular Brain Research 110:152-157
- 89) Chaudhury, A.B., K.M. Gerecke, J.M. Wyss, **D.G. Morgan**, M.N. Gordon, & S.I. Carroll (2003). Neuregulin-1 and ErbB4 immunoreactivity is associated with neuritic plaques in Alzheimer Disease brain and in a transgenic model of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology 62:42-54. (60)
- 90) **Morgan, D**, Jantzen, P. and M. Gordon (2003). Clearance of amyloid by vaccination and nitro-NSAIDs in APP+PS1 transgenic mice. In *Alzheimer's Disease and Related Disorders: Research Advances*. K. Iqbal and B. Winblad (eds) Ana Aslan Academy of Aging,

Curriculum Vitae, David G. Morgan

Bucharest, Romania, pp 525-532.

- 91) Joseph, J.A., N.A. Denisova, G. Arendash, M. Gordon, D. Diamond, B. Shukitt-Hale and **D. Morgan** (2003). Blueberry supplementation enhances signaling and prevents behavioral deficits in Alzheimer disease model. Nutritional Neuroscience 6:153-162 (236)
- 92) Dickey, C.A., J.F. Loring, J. Montgomery, M.N. Gordon, P.S. Eastman and **D. Morgan** (2003) Selectively Reduced Expression of Synaptic Plasticity-Related Genes in APP+PS1 Transgenic Mice. Journal of Neuroscience 23:5219-5226 (147)
- 93) Boyett KW, DiCarlo G, Jantzen PT, Jackson J, O'Leary C, Wilcock D, **Morgan D**, Gordon MN. (2003). Increased fibrillar beta-amyloid in response to human C1q injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochemical Research 28:83-93.
- 94) Wilcock, D.M., Munireddy, S.K., Rosenthal, A., Ugen, K.E., Gordon, M.N. and **Morgan, D.**(2004). Microglial activation facilitates AB plaque removal following intracranial anti-AB antibody administration. Neurobiology of Disease 15:11-20. (132)
- 95) Dickey,C.A., Gordon,M.N., Mason, J.E., Wilson, N.J., Diamond, D.M., Guzowski, J.M. and **Morgan,D.** (2004) Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. Journal of Neurochemistry 88:434. (49)
- 96) Li, Q., C Cao, B Chackerian, J Schiller, M Gordon, KE Ugen and **D Morgan** (2004). Overcoming antigen masking of anti-A β antibodies reveals breaking of B cell tolerance in A β immunized amyloid precursor protein transgenic mice. BMC Neuroscience, 5: 19
- 97) **Morgan, D**, and BD Gitter (2004). Evidence supporting a role for anti-A β antibodies in the treatment of Alzheimer's disease. Neurobiology of Aging, 25:605-608
- 98) Garcia, M. F., M. N. Gordon, M. Hutton, J. Lewis, E. McGowan, C. A. Dickey, **D. Morgan** and G.W. Arendash (2004). The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer's transgenic mice. Neuroreport 15:73-77
- 99) Ambegaonkar M,U., Nagle, A.S., Breitner, J.C., Deleon, J., Alamed, J., Wilson, N., **Morgan, D.**, and Gordon, M.N. (2004). The histamine H2-receptor antagonist cimetidine activates microglia in APP+PS1 transgenic mice. Brain Aging 4:25-40.
- 100) Wilcock, D., A. Rojiani, A. Rosenthal, J. Alamed, D. Wilson, N. Wilson, M. Freeman, M. Gordon, **D. Morgan** (2004). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. Journal of Neuroscience, 24:6144-6151 (185)
- 101) Dickey, C.A, D, Demesquita, **D. Morgan** and K. Pennypacker (2004). Induction of several immediate early genes by nerve growth factor in primary neurons and differentiated neuro2A cells. Neurosci Lett. 366: 10-14

Curriculum Vitae, David G. Morgan

- 102) Herber, D.L., E.G. Severance, J. Cuevas, **D. Morgan**, and M.N. Gordon (2004). Biochemical and histochemical evidence of nonspecific binding of $\alpha 7$ nAChR antibodies to mouse brain tissue. J. Histochem. Cytochem. 52:1367-1376 (54)
- 103) Townsend, K.P. D.R. Shytle, Y. Bai, N. San, J. Zeng, M. Freeman, F. Fernandez, **D. Morgan**, P.R. Sanberg and J. Tan (2004). Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J. Neurosci. Res., 78:167-176
- 104) Gasparini, L., E. Ongini, D. Wilcock, and **D Morgan** (2004). Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Research Reviews, 48: 400-408. (58)
- 105) Herber; D.L., L.M. Roth, D. Wilson, N. Wilson; J.E. Mason, **D. Morgan** and M.N. Gordon (2004). Time-dependent reduction in A β levels after intracranial LPS administration in APP transgenic mice. Experimental Neurology, 190(1):245-253. (71)
- 106) Patel, N.V., M.N. Gordon, K. E.. Connor, R.A. Good, R.W. Engelman, J. Mason, **D.G. Morgan**, T.E. Morgan, C.E. Finch (2005). Caloric Restriction Attenuates A β -deposition in Alzheimer Disease Models. Neurobiology of Aging, 26:995-1000 (144)
- 107) Ewers M., M.N. Gordon, **D. Morgan** and D Woodruff-Pak (2005). Assessing Associative Learning changes of Alzheimer's disease in transgenic APP + PS1 mice: Relation to cortical amyloid pathology. Neurobiol Aging 27:1118-28
- 108) Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, **Morgan D.** (2004). Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 1:24. (207)
- 109) Townsend, KP, T Town, T Mori, L-F Lue, Doug Shytle, P Sanberg, **D Morgan**, F Fernandez, RA. Flavell and J Tan (2005) CD40 signaling regulates innate and adaptive activation of microglia in response to A β . Eur J Immunol., 35:901-910 (72)
- 110) Dickey CA, Gordon MN, Wilcock DM, Herber DL, Freeman MJ, **Morgan D.**(2005) Dysregulation of Na⁺/K⁺ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neurosci. 6:7.
- 111) **Morgan, D** (2006) Immunotherapy for Alzheimer's Disease. Journal of Alzheimer's Disease, 9:425-432. 100 years of progress issue (44)
- 112) **Morgan D** (2006) Cognitive impairment in transgenic mouse models of amyloid deposition. In *Animal Models of Cognitive Impairment*, E. Levin and J Buccafusco (eds)., CRC Press, Boca Raton, 183-198.
- 113) **Morgan, D**, M Gordon, J. Tan, D. Wilcock and A.M. Rojiani (2005). Dynamic complexity of

- the microglial activation response in transgenic models of amyloid deposition. Implications for Alzheimer's therapeutics. Journal of Neuropathology and Experimental Neurology 64:743-53. (97)
- 114) Wecker L. and **D. Morgan** (2005). Treatment of Parkinson's and Alzheimer's Diseases. In *Brody's Human Pharmacology: Molecular to Clinical*. Minneman, K, L. Wecker, J. Larner and T.M Brody (eds). Elsevier Mosby Press, Philadelphia, pp 277-284.
- 115) **Morgan, D** (2006), Modulation of Microglial Activation State Following Passive Immunization in Amyloid Depositing Transgenic Mice. Neurochemistry International 49: 190-194
- 116) **Morgan, D.** (2005). Mechanisms of A-beta Plaque Clearance Following Passive A-beta Immunization. Neurodegenerative Disease, 2:261-266.
- 117) Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, **Morgan D**, Hardy J, Town T, Tan J. (2005). Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. Journal of Neuroscience 25:8807-8814. (252)
- 118) Townsend KP, Shytle DR, Bai Y, San N, Zeng J, Freeman M, Mori T, Fernandez F, **Morgan D**, Sanberg P, Tan J. (2004). Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J Neurosci. Res.78:167-76. (41)
- 119) Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN and **D Morgan** (2006). Intracranial administration of deglycosylated C-terminal-specific anti-A β antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of Neuroinflammation 3: 11
- 120) Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN and, **D Morgan** (2006) Deglycosylated anti-A β antibodies reverse cognitive deficits, dramatically reduce parenchymal amyloid with minimal vascular consequences in aged APP transgenic mice. Journal of Neuroscience 26::5340-46. (85)
- 121) Herber DL, Maloney JL, Roth LM, Freeman MJ, **Morgan D**, Gordon MN. (2006). Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia.53:382-91.
- 122) **Morgan D** and Gordon, MN (2007). Immunotherapy for Alzheimer's Disease. in *NeuroImmune Pharmacology*. Gendelman H and Ikezu T (eds). in press
- 123) Wilcock DM, Jantzen PT, Li Q, **Morgan D** and Gordon MN (2007). A β vaccination, but not nitro-NSAID treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144:950-960 (70)
- 124) Karlinski R, Wilcock D, Dickey C, Ronan V, Gordon MN, Zhang W, **Morgan D*** and

Curriculum Vitae, David G. Morgan

- Tagliatela G (2006) Up-Regulation of Bcl-2 in APP Transgenic Mice is Associated with Neuroprotection. Neurobiology of Disease 25:179-188. * **corresponding author**
- 125) Alamed J, Wilcock DM, Diamond DM, Gordon MN and **Morgan D** (2006). Two-day radial-arm water maze learning and memory task; robust resolution of amyloid related memory deficits in transgenic mice. Nature Protocols 1:1671-1679. (30)
- 126) Wilcock DM, Gordon MN, **Morgan D** (2006). Quantification of Cerebral Amyloid Angiopathy and Parenchymal Amyloid Plaques with Congo Red Histochemical Stain. Nature Protocols 1:1591-1595. (30)
- 127) Li,Q-Y, Gordon MN, Cao C, Ugen KE and **Morgan D** (2007). Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-A β antibodies. BMC Neuroscience 8:22 (11 pages)
- 128) **Morgan, D** (2007). Amyloid, memory and neurogenesis. Experimental Neurology, 205:330-5
- 129) Golub MS, Germann SL, Mercer M, Gordon MN, **Morgan DG**, Mayer LP, Hoyer PB. Relat (2007). Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. Neurobiology of Aging.
- 130) Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, Ehrhart J, Shytle RD, Giunta B, **Morgan D**, Town T, Tan (2007). Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A. 104:2507-12 (50)
- 131) Dickey,CA, Koren, J, Zhang, Y-J, Xu, Y-F, Jinwal, UK, Birnbaum, MJ, Monks, B, Sun, M, Cheng, JQ, Patterson, C, Bailey, RM, Dunmore, J, Soresh, S, Leon, C, **Morgan, D**, Petrucelli, L (2008) Akt and CHIP co-regulate tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. 105:3622-7 (51)
- 132) **Morgan, D** & M.N. Gordon (2008). Amyloid hyperactivity and metabolism. Behavioral Neuroscience. 122:730-2.
- 133) Li Q, M. Gordon, M.A. Etienne, R P. Hammer & **D. Morgan** (2008). Contrasting in vivo effects of two peptide-based amyloid β -protein aggregation inhibitors in a transgenic mouse model of amyloid deposition. Cell Transplantation 17:397-408
- 134) Karlinski, RA, A Rosenthal, J Alamed, V Ronan, MN Gordon, PE Gottschall, J Grimm, J Pons and **D Morgan**, (2008). Deglycosylated anti-A β antibody dose-response effects on pathology and memory in APP transgenic mice. J. Neuroimmune Pharmacol. 3:187-97
- 135) Carty N., K Nash D Lee, M. Mercer PE Gottschall C. Meyers N Muzyczka, MN Gordon and **D. Morgan** (2008). Adeno-Associated Viral Vector Mediated Gene Delivery of Endothelin Converting Enzyme Reduces A β Deposits in APP+PS-1 Transgenic Mice. Molec. Therapy 16:1580-6

Curriculum Vitae, David G. Morgan

- 136) Obregon D, Hou H, Bai Y, Nikolic WV, Mori T, Luo D, Zeng J, Ehrhart J, Fernandez F, **Morgan D**, Giunta B, Town T, Tan J. (2008) CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol Dis.29:336-53.
- 137) Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N, Freeman MJ, **Morgan D**, Gordon MN.(2007) Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol.;2:222-31 (38)
- 139) **Morgan D**, Munireddy S, Alamed J, Deleon J, Diamond DM, Bickford P, Hutton M, Lewis J, McGowan E, Gordon MN. (2008). Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice . J Alzheimers Dis. 15:605-14.
- 140) Dickey C, C Kraft, U Jinwal, J Koren, A Johnson, L Anderson, L Lebson, D Lee, D Dickson, R de Silva, LI Binder, **D Morgan**, and J Lewis (2009). Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. The American Journal of Pathology.,. 174:228-238.
- 141) **Morgan D**, Landreth G, Bickford P. (2009) The promise and perils of an Alzheimer disease vaccine: a video debate. J Neuroimmune Pharmacol.;4(1):1-3
- 142) Karlinski RA, Rosenthal A, Kobayashi D, Pons J, Alamed J, Mercer M, Li Q, Gordon MN, Gottschall PE, and **Morgan D** (2009). Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. J. Neuroscience 29:4964-71
- 143) Jinwal UK, Miyata Y, Koren J 3rd, Jones JR, Trotter JH, Chang L, O'Leary J, Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ, Zuiderweg ER, Gestwicki JE, Dickey CA. (2009). Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability. J. Neurosci 29:12079-12088
- 144) Lord A, Englund H, Söderberg L, Tucker S, Clausen F, Hillered L, Gordon M, **Morgan D**, Lannfelt L, Pettersson FE, Nilsson LN. (2009) Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J. 276(4):995-1006.
- 145) Zhu Y, Obregon D, Hou H, Giunta B, Erhart J, Fernandez F, Mori T, Nikolic W, Zhao Y, **Morgan D**, Town T, Tan J. (2009) Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology. J Cell Mol Med. 2011 15:327-338
- 146) **Morgan D**.(2009) The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets. 2009 Mar;8(1):7-15
- 147) Ajmo JM, Bailey LA, Howell MD, Cortez LK, Pennypacker KR, Mehta HN, **Morgan D**, Gordon MN, Gottschall PE (2010). Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice overexpressing APPsw. J Neurochem 113: 784-795, PMID: 20180882

Curriculum Vitae, David G. Morgan

- 148) Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, Li Q, Szekeres K, Jinwal U, Koren J, Dickey CA, Gottschall PE, **Morgan D***, Gordon MN (2010). Trafficking CD11b-Positive Blood Cells Deliver Therapeutic Genes to the Brain of Amyloid-Depositing Transgenic Mice. J Neurosci. 30:9651-8. PMID: 20660248. * corresponding author
- 149) Li, QY, MN Gordon, B Chackerian, J. Alamed, KE Ugen, and **D Morgan** (2010). Virus-like peptide vaccines against A β M-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. J Neuroimmun Pharmacol. 5:133-42. PMID: 20066498
- 150) Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, **Morgan D.** (2010). LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation. 16; 56. PMID: 20846376
- 151) Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, Golde TE, Gordon MN, **Morgan D***, Nash K. (2010). Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods. 194(1):144-53. PMID: 20951738. * corresponding author
- 152) **Morgan D.** (2011) Immunotherapy for Alzheimer's disease. J Intern Med. 269(1):54-63. PMID: 21158978
- 153) **Morgan D.**, and A.G. Smith (2011) Why age (and timing) really matter in developing drugs for neurodegenerative disease. Therapy 8:459-461
- 154) Wilcock, DM, **D Morgan**, MN Gordon, TA Taylor, LA Ridnour, DA Wink and CA Colton (2011). Activation of matrix metalloproteinases following anti-Abeta immunotherapy; implications for microhemorrhage occurrence. J Neuroinflamm. 8:115 (7 pages). PMID: 21906275
- 155) Diana W Shineman, Guriqbal S Basi, Jennifer L Bizon, Carol A Colton, Barry D Greenberg, Beth A Hollister, John Lincecum, Gabrielle G Leblanc, Linda (Bobbi) H Lee, Feng Luo, **Dave Morgan**, Iva Morse, Lorenzo M Refolo, David R Riddell, Kimberly Scarce-Levie, Patrick Sweeney, Juha Yrjnheikki and Howard M Fillit (2011). Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimer's Research and Therapy 3:28 (13 pages).
- 156) Li, Q., L. Lebson, D.C. Lee, K Nash, J. Grimm, A. Rosenthal, M.B. Selenica, **D. Morgan***, M. N. Gordon (2012). Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load. J Neuroimmune Pharmacol. 7:202-14. PMID: 22198698
* corresponding author
- 157) Selenica, M.J., M. Brownlow J.P. Jimenez, D.C. Lee, C.A. Dickey, M.N. Gordon and **D. Morgan** (2012). Amyloid oligomers exacerbate tau pathology in a mouse model of

Curriculum Vitae, David G. Morgan

- tauopathy. Neurodegener. Dis. PMID: 22796753
- 158) Lee DC, Rizer J, Hunt JB, Selenica ML, Gordon MN, **Morgan D.** (2012) Experimental manipulations of microglia in mouse models of Alzheimer's pathology. Activation reduces amyloid but hastens tau pathology. *Neuropathol Appl Neurobiol* 39:69-85. PMID: 23171029
- 159) Wilcock DM, Zhao Q, **Morgan D**, Gordon MN, Everhart A, Wilson JG, Lee JE, Colton CA (2011). Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. *ASN Neuro.* 3:249-58. PMID: 21995345
- 160) Nash KR, Lee DC, Hunt JB Jr, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M, Guang-Yu Yang C, Savalia M, Gemma C, Bickford PC, Gordon MN, **Morgan D.** (2013) Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. *Neurobiol Aging.* 2013 Jun;34(6):1540-8.PMID: 23332170
- 161) Lee DC, Ruiz CR, Lebson L, Selenica ML, Rizer J, Hunt JB Jr, Rojiani R, Reid P, Kammath S, Nash K, Dickey CA, Gordon M, **Morgan D.**(2013). Aging enhances classical activation but mitigates alternative activation in the central nervous system. *Neurobiol Aging.* 2013 Jun;34(6):1610-20. PMID: 23481567
- 162) Carty N, Nash KR, Brownlow M, Cruite D, Wilcock D, Selenica ML, Lee DC, Gordon MN, **Morgan D.** (2013) Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. *PLoS One.* 8(3):(10 pages).PMID: 23555730
- 163) Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, Reid P, Mouton PR, **Morgan D**, Gordon MN. (2013). Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. *J Neuroinflammation.* 2013 Jul 17;10:86 PMID: 23866683
- 164) Brownlow ML, Benner L, D'Agostino D, Gordon MN, **Morgan D.** (2013). Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. *PLoS One.* 12;8(9):e75713. PMID: 24069439

Invited Presentations (since 2000)

January 8, 2000. Correlation of amyloid with behavior in transgenic mice. Winter Conference on the Neurobiology of Memory, Park City UT

February 22, 2000. Animal models of Alzheimer's disease as an approach to therapeutics. USF Institute on Aging Public Information Program, Clearwater FL

March 24, 2000. Transgenic mouse models of Alzheimer's Disease. Correlations between amyloid and behavior. Dept. of Biology, USF, Tampa FL

June 23, 2000. Vaccination NSAIDs and microglia in doubly transgenic mice. Mayo Clinic, Jacksonville, FL

July 8, 2000. A β vaccination protects from memory loss in APP+PS1 transgenic mice. 7th International Conference on Alzheimer's Disease, Washington, DC

October 23, 2000 Behavioral endpoints in transgenic mouse models of Alzheimer's disease: Effects of vaccination. Elan Pharmaceuticals, South San Francisco, CA

October 31, 2000. Pathobiology of Alzheimer's disease and rational design of therapeutics. American Osteopathic Association, Invited Lecture, Orlando, FL.

1 March 2001. Modulation of amyloid deposition in a transgenic mouse model of Alzheimer's disease. Oklahoma Medical Research Foundation, Oklahoma City, OK.

2 April 2001. Alzheimer's Disease. Pharmacological Approaches. Haley Veteran's Administration Hospital, Tampa FL

3 April 2001. Research Update. Alzheimer's Disease Vaccine. Alzheimer's Association Convention, Tampa Bay Chapter, Tampa FL.

20 April, 2001. Anti-inflammatory drugs in a mouse model of amyloid deposition. AstraZeneca Inc, Wilmington DE

7 May, 2001. Update on Alzheimer's Disease. National Association of Retired Federal Employees Convention, Tampa FL

11 May, 2001. NCX 2216 reduces amyloid plaque load in a transgenic model of Alzheimer's disease, Nitric Oxide and Cox Satellite Symposium, Capri, Italy

14 May 2001. Microglial activation in a mouse model of amyloid deposition. University of Milano-Bicocca, Milan, Italy

21 May, 2001. The new pharmacology of Alzheimer's disease. Alzheimer's Association Tampa Chapter Meeting, Brandon FL

Curriculum Vitae, David G. Morgan

- 4 June 2001. The effect of dietary macro- and micro-nutrients on amyloid pathology in a transgenic model of Alzheimer's disease. American Aging Association, Madison WI
- 7 June 2001. What's in the future for Alzheimer's disease treatment? The vaccine and other research updates. USF Geriatric Institute, Tampa FL
- 15 August 2001. A transgenic model of amyloid deposition. Joy McCann Culverhouse Airway Disease Center Molecular Medicine Seminar, USF Internal Medicine, Tampa FL.
- 24 September 2001. Cognitive improvements after beta amyloid immunization in a mouse model of plaque formation. Laura Chalk Rowles Lecture, McGill Center for Studies on Aging, Montreal, Canada.
- 29 September 2001. Amyloid vaccination in a transgenic mouse model of amyloid deposition. Dept. of Neuroscience, University of Florida, Gainesville, FL.
- 5 October 2001. Neurodegenerative Disease- Vaccines for Alzheimer's Disease. Invited presentation Southeastern Pharmacological Society meeting, Clearwater FL.
- 1 November 2001. "Bap"tists versus "Tau"ists: Competing Theories about Alzheimer's Disease. Phi Beta Kappa Association, Tampa, FL
- 9 November 2001. The role of transgenic mouse models of amyloid deposition in Alzheimer's disease research. Invited Speaker at Brain Aging, Identifying accelerators and brakes, San Diego CA.
- 14 November 2001. Effects of NCX-2216 in APP+PS1 transgenic mice. GlaxoSmithKlein CEDD, San Diego, CA
- 11 December 2001. Functional consequences of ab immunization in the APP+PS1 transgenic mouse . American College of NeuroPsychopharmacology Meeting Kona, HI.
- 15 January 2002. Transgenic models of amyloid deposition; Vaccines, NSAIDs and gene expression. Winter Conference on Learning and Memory. Park City, UT
- 18 January 2002. Pharmacological modulation of a mouse model of amyloid deposition. Dept of Biochemistry and Molecular Biology, U South Florida, Tampa FL
- 12 February 2002. Update on transgenic models of amyloid deposition. AstraZeneca, Wilmington DE
- 15 February 2002. The role of transgenic mouse models of amyloid deposition in Alzheimer's disease research. Chicago Chapter Society for Neuroscience Annual Meeting. Chicago IL
- 26 February 2002. Phenotypic modification of an mouse model of amyloid deposition. Wyeth-Ayerst Laboratories, Princeton NJ.

Curriculum Vitae, David G. Morgan

- 6 April, 2002. A β Vaccination in an APP+PS1 Transgenic Mouse Model of Amyloid Deposition. Springfield Symposium on Therapies for Alzheimer Disease, Geneva, Switzerland.
- 2 May 2002. Protection from Memory Deficits by Amyloid Vaccines in a Transgenic Mouse Model of Amyloid Deposition. Army Institute of Research Basic Aspects of Vaccines Symposium, Bethesda MD
- 8 June 2002. Inflammatory mechanisms in brain aging: Possible sites for intervention. American Aging Association Meeting, San Diego, CA
- 25 June 2002. Modulation of amyloid deposition and learning in an APP+PS1 transgenic model by A β vaccination and a Nitro-NSAID, SRI symposium on Neurodegeneration, Princeton, NJ
- 9 July 2002. Vaccines, NSAIDs and Microglial Activation in a Mouse Model of Amyloid Deposition. Eli Lilly Inc, Indianapolis IN
- 23 July 2002. Clearance of amyloid by vaccination. Invited symposium presentation, 8th International Conference on Alzheimer's Disease, Stockholm Sweden
- 9 September 2002. Immunotherapeutic approaches to a transgenic mouse model of amyloid deposition. University of Nebraska, Omaha NE
- 22 October, 2002. Lunch with a Scholar: Update on Alzheimer's Disease. Northern Trust Bank, Indian Rocks Beach FL
- 30 January 2003. Is Excess A β Amyloid A Necessary Condition for Alzheimer's Disease? Winter Conference on Brain Research, Snowbird UT.
- 24 February 2003. Curing dementia in an Alzheimer's Mouse. Voices from the Inside, USF Institute on Aging, Tampa FL.
- 11 May 2003. Synaptic gene expression in APP+PS1 transgenic mice. 6th International Conference on AD/PD, Seville, Spain
- 16 June 2003. Amyloid Immunotherapy, Microglia and Memory in APP+PS1 Transgenic Mice, University of California, Irvine, CA
- 17 June 2003. Making memories in mouse models of amyloid deposition. University of Southern California, Los Angeles, CA
- 27 July 2003. Are A β Vaccines the Answer to Treating Alzheimer's Disease? Challenging Views, Cincinnati, OH
- 16 September 2003. Evidence fo Anti-A β Immunotherapy in Alzheimer's Disease. Neurology Grand Rounds, Duke University, Durham NC
- 17 September 2003. Microglia Molecules and Memory in a Mouse Model of Amyloid Deposition.

Curriculum Vitae, David G. Morgan

Ortho-McNeil lecture in Alzheimer's Research. Duke University, Durham, NC

11 November 2003. Is Inflammation Beneficial or Detrimental in Neurodegenerative Disease? Neurological Disease Foundation, New Orleans, LA.

10 December 2003. Vaccination and NSAIDs in AD models. Glial Inflammation in Disease NIH Workshop. Washington, DC

16 December 2003. Vaccines as therapy for Alzheimer's dementia. Bristol Myers Squibb Consultants Panel, New York, NY

5 January 2004. Treatment approaches to curing Alzheimer's disease. AFAR symposium, Ocala FL

5 February 2004. New treatments for Alzheimer's Disease. State of Florida Alzheimer's Summit Tallahassee, FL

23 February 2004. Mechanisms of amyloid-associated memory dysfunction. Winter Conference on Neural Plasticity, St. Lucia, West Indies.

14 May 2004. Synaptic changes in APP+PS1 transgenic mouse models of amyloid deposition. Stereology Workshop, North Captiva Island, FL.

18 May 2004. Anti-amyloid Immunotherapy for Alzheimer's Disease: Effects on a Transgenic Model. Burnham Institute, La Jolla, CA.

19 May 2004. Anti-amyloid immunotherapy effects on learning and memory in transgenic mouse models of amyloid deposition. Dept. of Neurosciences, University of California, San Diego, CA.

19 August 2004. Prospects for Success of Anti-A β Immunotherapy. Lessons From Mouse Models of Amyloid Deposition. Pfizer Inc. Groton CT

23 August 2004. Immunochemical approaches to reducing brain amyloid. Merck Inc, West Point, PA

14 September 2004. Learning and memory in APP+PS1 transgenic mice. NIA-Johns Hopkins Conference on Assessing Cognition for Emerging Therapeutics in AD, Baltimore MD

14 October 2004. Immunotherapy for Alzheimer's Disease: Lessons from transgenic Mice. Sigma Xi Tampa Chapter, Tampa, FL

13 March 2005. Anti-A β immunotherapy improves memory in aged app transgenic mice in spite of elevated vascular amyloid and microhemorrhage, 7th International Conference on AD/PD, Sorrento Italy

4 April 2005. Vaccination versus passive immunotherapy in the treatment of Alzheimer's.

Curriculum Vitae, David G. Morgan

- American Society for Pharmacology and Experimental Therapeutics Meeting.
San Diego, CA
- 12 April 2005. Immunotherapy for Alzheimer's disease. Lessons from transgenic mouse models
Florida Atlantic University, Boca Raton FL
- 8 June 2005. Immunotherapy as an approach to Alzheimer's disease. 9th International
Conference on Neural Transplantation and Repair, Taipei, Taiwan.
- 28 June 2005. Microglial activation in APP transgenic mice after passive immunization with
anti-A β antibodies. American Society for Neurochemistry, Madison WI
- 18 August 2005. Artifacts in immunoassays of anti-A β antibody titers in serum. Talecris Inc.
Research triangle Park, NC
- 10 November 2005. Immune Therapy for Alzheimer's Disease. National Parkinsons Foundation
9th International Symposium, Washington DC.
- 24 January 2006. Microglial activation in APP transgenic mice. Winter Conference on Brain
Research, Steamboat Springs, CO.
- 7 April 2006. Amyloid Clearance in APP Transgenic Mice using Passive Immunization. National
Institute on Aging Gerontology Research Center, Baltimore, MD
- 20 April 2006. Passive Immunotherapy in a Mouse Model of Amyloid Deposition. 9th International
Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva Switzerland.
- 4 May 2006. Modulating Microglia and Amyloid Clearance in APP Transgenic Mice. University of
Cincinnati Neuroscience Program, Cincinnati OH.
- 15 May 2006. Immunotherapy against amyloid as a treatment for Alzheimer's disease: A
therapeutic roller coaster. American Society for Neural Therapy and Repair Annual
Meeting, Clearwater FL
- 16 May 2006. Update on Alzheimer's therapeutics. Patient Safety Research Center, Tampa FL
- 19 July 2006. Microglia Aging and Alzheimer's Disease. 9th International Meeting on Alzheimer's
Disease. Madrid Spain
- 7 September 2006. Immunotherapy, Vascular Amyloid and Microhemorrhage. Pfizer Inc, Groton
CT
- 2 October 2006. Anti-A β antibodies as a treatment for Alzheimer's disease. Karolinska Institute,
Stockholm, Sweden
- 3 October 2006. Microglial activation and amyloid clearance using immunotherapy in transgenic
mice. University of Uppsala, Uppsala Sweden

Curriculum Vitae, David G. Morgan

- 5 October 2006 Immunotherapy against A β in a mouse model of amyloid deposition. AstraZeneca Symposium on Alzheimer's Disease. Sodertalje, Sweden
- 6 November 2006. Immunotherapy for Treatment of Alzheimer's Disease. Southeastern Pharmacological Society Annual Meeting, Oxford, MS
- 10 January 2007 Immunotherapy for Alzheimer's Disease. Medical College of Georgia, Augusta GA
- 12 March 2007. Immunotherapy as a treatment for Alzheimer's disease, University of Zurich, Zurich Switzerland
- 19 March 2007. Increased vascular amyloid and microhemorrhage is observed with amyloid reductions caused by A β vaccination but not nitro-NSAIDs. 8th International AD/PD Conference, Salzburg Austria
- 19 April, 2007. Immunotherapy for Alzheimer's disease. Conference on Alzheimer's Disease: From Molecular Mechanisms to Drug Discovery. Punta Cana, Dominican Republic
- 15 June 2007. Molecular Therapeutics for Alzheimer's. SRI International, Palo Alto, CA
- 26 June 2007 Antibodies for Alzheimer's. From mouse models to clinical trials. Signature Program in Neuroscience Seminar, U South Florida, Tampa FL
- 29 Aug 2007. Immunotherapeutics for Alzheimer Disease. University of Maryland College of Pharmacy, Baltimore MD
- 8 September 2007. Gene therapy with Amyloid Degrading Proteases in Mouse Models of Amyloid Deposition. Symposium on Engineering Negligible Senescence. University of Cambridge, England
- 14 September 2007. Are APP transgenic mice good models of memory loss in Alzheimer's disease?. Alzheimer's Disease Research Symposium. AstraZeneca Pharmaceuticals, Sodertalje, Sweden
- 12 October 2007. Oligomeric A β as a toxic agent in Alzheimer's Disease. Baxter Inc, Northbrook IL
- 16 January 2008. Immunotherapy to remove amyloid deposits. Potential as a therapeutic and usefulness as a research tool. University of Texas Health Sciences Center, San Antonio TX
- 6 February 2008. Immunotherapy for Alzheimer's disease". Columbia University College of Medicine. New York NY
- 18 February 2008. Therapeutic Reduction of Beta-Amyloid in Transgenic Mice. Sils Maria Conference, St Moritz, Switzerland

Curriculum Vitae, David G. Morgan

- 24 March, 2008. Antibody mediated clearance of amyloid deposits and restoration of memory. New York Academy of Science, New York, NY
- 27 July 2008. Microglial signal transduction mechanisms, Invited symposium presentation at International Congress on Alzheimer's Dementia, Chicago IL.
- 28 July 2008. Passive Immunotherapies as an Approach to Disease Modification in Alzheimer's Disease. Pfizer Educational Dinner Symposium, Chicago IL
- 26 August 2008. Immunotherapy as a treatment for Alzheimer's disease. Federation of European Neurological Societies, Madrid Spain.
- 26 September 2008. Amyloid immunotherapy. Role of microglia/macrophages. University of Southern California, Los Angeles CA
- 7 November 2008. New Models of Drug Discovery Linking Academia and Industry. Presentation to Hampton Roads Chamber of Commerce,
- 21 November 2008. Immunotherapeutic approaches to lowering amyloid in AD. UK-US International Alzheimer's Disease Symposium, Tampa FL
- 17 December, 2008. Development of Immunotherapy for Alzheimer's Disease. From Tribulations to Trials. University of Central Florida, Orlando FL
- 2 February 2009. Targeted Therapies for Alzheimer's Disease. Tampa Rotary Club, Tampa FL
- 27 February 2009, Molecular Therapeutic Approaches to Lowering Brain Amyloid; Immunotherapy and Gene Therapy. University of Kentucky, Lexington KY
- 5 March 2009. Immunotherapy and Gene Therapy Against Brain Amyloid. Northwestern University, Chicago IL
- 14 March 2009. Modulating A β with monocyte gene therapy. 9th International AD/PD Meeting, Prague, Czech Republic
- 26 March 2009. New Advances in Antibodies and Genes to Treat Alzheimer's Disease. Museum of Science and Industry, Tampa FL
- 28 March 2009. Advances to treat Alzheimer's Disease. Florida Elder Law Conference, Tampa FL
- 22 April 2009. Biomedical Ethics in the 21st Century. Moffitt Cancer Center, Tampa FL
- 10 June 2009 Molecular Approaches to Lowering Brain Amyloid; Immunotherapy and Gene Therapy. Linkoping Sweden
- 14 June 2009. Immunotherapy Against A β as a Treatment for Alzheimer's Disease. Conference on Neuroimmunology, Kuopio Finland

Curriculum Vitae, David G. Morgan

15 June 2009. Classical versus Alternative Activation of Microglia in Aging and Alzheimer's Disease. Kuopio Finland

24 June 2009. Molecular Approaches to Lowering Brain Amyloid. Georgetown University, Washington DC

5 October 2009. New Developments in Alzheimer's Disease. Exchange Club, Tampa FL

30 November 2009. Research Developments at the Byrd Alzheimer Institute, Rotary Club, Plant City FL

4 December 2009. Molecular Therapeutic for Alzheimer's Disease . Third International Brain Conference. Orlando FL.

10 December 2009. Molecular Therapeutics for Alzheimer's Disease. Texas A&M University. College Station TX.

11 February 2010. Aging and Alzheimer's Disease. American Federation for Aging research Fundraiser. Miami FL

19 March 2010. Immunotherapeutic Approaches to Reducing Brain Amyloid. Alzheimer's Research Trust Annual Meeting. Southampton, England

7 May 2010. Immunotherapeutic Approaches to Lowering Abeta. Lundbeck Pharmaceuticals, Copenhagen, Denmark

13 May 2010. Biology of Alzheimer's Disease. Lifelong Learning seminar, Tampa FL

21 June 2010. Measurement of Tau Pathology in Transgenic Mice, Alzheimer's Drug Development Foundation, New York

30 June 2010. Advances in Alzheimer's Research and Prevention. Tampa FL

10 SEP 2010. Gene Therapy for Alzheimer's Disease. University of Linköping, Linköping Sweden

13 September 2010. Immunotherapy for Alzheimer's Disease. Axel Key Symposium, Karolinska Institute, Stockholm Sweden

15 September 2010. Specificity of antibodies directed against A β in mouse models of amyloid deposition. Bioarctic Inc, Stockholm Sweden.

21 September 2010. Alzheimer's disease in Florida. Us Against Alzheimer's Press Breifing. Clearwater FL

4 October 2010. Update on the USF Health Byrd Alzheimer Institute. Tampa Exchange Club,

Curriculum Vitae, David G. Morgan

Tampa FL

- 21 October 2010. Drug Development for Alzheimer's Disease. NIA Advisory Panel, Bethesda MD
- 7 September 2010. Alzheimer's Update. Radio Interview Fort Myers FL
- 21 September 2010. Alzheimer's in Florida. Us Against Alzheimer's Town Hall Meeting, Clearwater FL
- 4 October 2010. Alzheimer's Update, Tampa Exchange Club, Tampa FL
- 4 November 2010. Alzheimer's Update, NARFE Plant City Chapter Meeting, Plant City FL
- 27 January 2011. Monocytes and Gene Therapy in the Central Nervous System. Lundbeck Pharmaceuticals, Paramus NJ
- 10 March 2011. Opposing Roles of Microglial Activation in Amyloid Depositing and Tau Depositing Mice. 11th AD/PD International Symposium. Barcelona, Spain
- 16 March 2011. Different Roles of Microglial Activation in Amyloid Depositing and Tau Depositing Mice. 2nd Venusberg International Conference on Neuroinflammation, Bonn Germany.
- 25 March 2011. Update on Byrd Alzheimer's Institute. Sanibel Yacht Club, Sanibel Florida
- 29 March 2011. Immunotherapy for Alzheimer's Disease. University of Central Florida, Research Day Invited Speaker. Orlando FL
- 31 March 2011. Immunotherapy in Mouse Models of Amyloid Deposition. Merck Pharmaceuticals, West Point PA.
- 20 April 2011. Update on Alzheimer's, Westshore Rotary Club, Tampa FL
- 27 April 2011. Aging and Alzheimer's, Alzforum Web Symposium. Internet.
- 27 May 2011. Immunotherapy in mouse models of amyloid deposition. 2nd International Conference on Neurodegenerative Disorders, Uppsala Sweden.
- 19 July 2011. Microglial activation in Aging and Alzheimer's Disease. Brain and Mind Institute, University of Sydney, Sydney, Australia
- 7 November 2011. Monocytes, Microglia, Aging and Alzheimer's Disease. Cleveland Clinic Dept of Neuroscience, Cleveland OH
- 11 November 2011. "Divergent effects of microglial activation on amyloid versus tau pathology. SFN Satellite Symposium on Neurotoxicity, Georgetown University, Washington DC
- 15 December 2011. News about research in Alzheimer's disease. Tampa City Council meeting,

Curriculum Vitae, David G. Morgan

Tampa FL

22 January 2012. Progress in winning the battle against Alzheimer's. Eagles Convention, Daytona Beach FL

24 January 2012. The problem of Alzheimer's in Florida. Press conference in Rotunda of State Capital, Tallahassee FL

31 January 2012. Progress in fighting Alzheimer's Disease. Tampa Downtown Rotary Club.
Tampa FL

13 February 2012. Progress in Alzheimer's research. South Tampa NARFE Chapter. Tampa FL

15 February 2012. Immunotherapy Against the A β Peptide in Mouse Models of Amyloid Deposition, Florida State University, Tallahassee FL

29 February 2012. The Biology of Alzheimer's Disease. Samaritan's Alzheimer's Auxiliary, Sun City Center FL

17 April, 2012. Update on Alzheimer's Disease. Lifelong learning seminar. Tampa FL

24 April 2012. State of the Science in Alzheimer's Disease, Corporate update satellite to American Association of Neurology Meeting, New Orleans LA

31 May 2012. Introduction to the Center for Memory C.A.R.E. at the USF Health Byrd Alzheimer's Institute in Tampa. Alzheimer's Educational Conference, West Palm Beach FL.

18 July 2012. Fractalkine signaling decreases tau pathology in tau depositing mice. Alzheimer's Association International Conference, Vancouver Canada.

3 August 2012. New developments in Alzheimer's Disease. Canterbury Towers, Tampa FL

5 August 2012. The under recognized problem of Alzheimer's disease. Tanglewood Manor, Jamestown, New York

8 August 2012. Research developments at the Byrd Alzheimer's Institute. BioFlorida chapter meeting, Tampa FL.

10 October 2012. Manipulation of the tau transgene phenotype in Tg4510 mice. Work in Progress, University of South Florida, Tampa FL

15 November 2012. Advances in Alzheimer's Research, St Petersburg FL

16 November 2012. Advances in Alzheimer's. New Age of Caregiving Symposium. St Petersburg FL

3 December 2012. Development of the Center for Memory C.A.R.E. Xuanwu Hospital, Beijing

Curriculum Vitae, David G. Morgan

China

4 December 2012. Advances in Alzheimer's Disease. Peking Medical Union, Beijing China

5 December 2012. Inflammation as the link between amyloid and tau pathology. Jiaotong University, Beijing China

7 December 2012. Manipulation of the tau transgene phenotype in a mousemodel of tau deposition. Dalian Medical University, Dalian China

10 December 2012. Inflammation the link between amyloid and tau pathology in Alzheimer's disease. Hong Kong University of Science and Technology, Hong Kong China

30 January 2013, Update on Alzheimer's Disease. Tampa Bay Senior Expo, St Petersburg FL

21 February 2013. Alzheimer's disease in 2020. Prime Timers group, Odessa FL

1 March 2013. Manipulation of the tau deposition phenotype in rTg4510 mice. 3rd Venusberg meeting on Neuroinflammation. Bonn Germany

4 March 2013. Role of microglial Activation in the Development of Alzheimer's Pathology. Italian Institute of technology, Genoa Italy

8 March 2013. Pharmacological Approaches to the Reversal of the Tau Phenotype in a Mouse Model of Tauopathy. 12th Annual AD/PD International Symposium, Florence, Italy.

11 April 2013. Alzheimer's past present and future. Alzheimer's and Parkinson's Association of Indian River County, Vero Beach, FL

22 April 2013. New treatments for Alzheimer's Disease. Alzheimer's Association Advocacy Forum, Washington DC

3 May 2013. The impact of Alzheimer's research in Florida. Alzheimer's Community Care Educational Conference, West Palm Beach FL

9 May 2013. New developments in Alzheimer's Disease. Conference of NARFE Leaders in Florida, Orlando FL

3 June 2013. Impact of Aging on Mouse Models of Alzheimer's Pathology. AFAR Grantees Meeting, Santa Barbara CA

15 June 2013 Immunotherapy for Protein Aggregation Disorders, Neuroscience School of Advanced Studies, Cortona Italy

10 July 2013. New approaches to Alzheimer's Disease; Prevention by 2020. NARFE National Convention Plenary speaker, Orlando FL

Curriculum Vitae, David G. Morgan

- 16 July 2013. Comments on the National Alzheimer's Plan milestones. A Researchers perspective. Alzheimer's Association International Meeting, Boston MA.
- 16 September 2013. Aging and neurodegeneration. Session Chairperson, BioFlorida annual meeting, Tampa FL
- 20 September 2013. Alzheimer's disease at the Byrd Institute, Charles University, Prague, Czech Republic
- 23 September 2013, A brief history of Alzheimer's disease, CTSI, Brno, Czech Republic.
- 29 October 2013, Geroscience. Testimony for Senate Select Committee on Aging, Washington DC
- 5 November 2013. Preventing Alzheimer's by 2020. Eckard College Lifelong Learning Society, St Petersburg FL
- 8 November 2013. New Approaches to preventing Alzheimer's. Purple Balloon Reception, Brevard Alzheimer's Foundation, Melbourne FL
- 22 November 2013. Why we need more Alzheimer's research funding. Alzheimer's Association Delegates meeting. Chicago, IL
- 4 November 2013. The Byrd Alzheimer's Institute. A Translational Research Center. Grand Rounds in Neuroscience. Michigan State University. Grand Rapids MI
- 10 December. The role of amyloid and tau in Alzheimer's disease. Nanoscience Institute, University of Central Florida, Orlando FL.
- Press Accounts- (since 2011)
- 4 Jan 2014 Letter to the Editor in Sarasota Herald Tribune
- 26 JUL 2013. Interview on WSRQ. Update on Alzheimer's
- 15 AUG 2013. Interview with CBC (Canada) on Alzheimer's Disease
- 3 Jun 2013 Contributed to "Spring Hill couple inspires research into coconut oil for Alzheimer's patients" in Tampa Bay Times
- 3 May 2013 Contributed to article "Coconut Oil Offers Hope for Alzheimer's" in Better Nutrition.
- 5 March 2013. Contributed to a story on "Helping to make Alzheimer's a memory" to north Tampa Neighborhood news
- 22 May 2012. Contributed to article on "CEO for a Day" in the USF Oracle
- 16 May 2012. Contributed to news account on Alzheimer's Summit for Bay News 9.
- 24 April 2012 Contributed to article on Amyvid in Tampa Bay Times
- 6 April 2012. Channel 8 News. Television interview regarding hazards of driving with Alzheimer's Disease.
- 26 January 2012. Contributed to news article on Alzheimer's in Sunshine State News
- 24 January 2012. Contributed to News Article in Tallahassee Democrat on Alzheimer's Disease
- 24 January 2012. Interviewed on television by Michael Vasilinda in Tallahassee

Curriculum Vitae, David G. Morgan

22 January 2012. Contributed to Editorial in Tampa Tribune on Alzheimer's disease

9 December 2011. Contributed to article in Sarasota Herald-Tribune on Alzheimer's disease.

21 November 2011 Contributed to article in St Petersburg Times on New clinical center at Byrd Alzheimer's Institute

15 November 2011. Contributed to an article on C.A.R.E center in Tampa Tribune.

27 August 2011. Contributed to article about Pat Summitt and Alzheimer's Disease in St Petersburg Times.

Curriculum Vitae, David G. Morgan

FACULTY MENTORED

Jun Tan (2002-2006 presently tenured Full Professor, USF Psychiatry)

Norma Alcantar (2005-2009 presently tenured Associate Professor; USF Biomedical Engineering)

Chad Dickey (2007- 2011 presently tenured Associate Professor, USF Molecular Medicine)

STUDENTS TRAINED

Postdoctoral Trainees (and current position)

Wayne Schreier, Chair of Physiology, Nova Southeastern Univ.

Marcia Gordon, Professor of Molecular Pharmacology, U South Florida

Giovanni DiCarlo, Pharmacist, Orlando

Megha Ambegoankor, Res Asst Prof. UCSD

Anan Nagle, Senior manager, Millipore, Singapore

Donna Wilcock, Asst Prof. University of Kentucky

Donna Herber, USF Div Patents and Licensing

Chad Dickey, Assistant Professor of Molecular Medicine, U South Florida

Qingyou Li, Research Associate, College of Medicine USF

Daniel Lee, Assistant Professor, College of Pharmacy, USF

Maj-Linda Selenica, Assistant Professor College of Pharmacy, USF

Aurelie Joly Amado (USF postdoc)

PhD Students (Primary Advisor)

at USC

James Goss, Prof, U Pittsburgh

Xiaorong Ou*

Kay-Min Chan*

Andrea Kelley*

Elysse Schauwecker*, Assoc Prof, Biochemistry, U Southern Cal

* completed PhD after Dr. Morgan's relocation to USF

at USF

Leigh Holcomb, Cephalon

Stan Benkovic, EPA

Kristal Wright, U Florida

Chad Dickey, U South Florida

Donna Wilcock, Duke

Rachel Karlnoski, Research Coordinator, Tampa General Hospital

Nikisha Carty, postdoc, Yale

Lori Lebson, postdoc, Johns Hopkins

Sulana Schroeder

Milene Lara

MS Students (Primary Advisor)

USC

Susan Schroeder

Gene Mazella

Curriculum Vitae, David G. Morgan

USF

Chun Wang
Paul Jantzen
Kerstie Estimible
Nikisha Carty
Debbie Henderson
Carolina Quiroga

MD Student Trainees

Jason DeLeon, Internal Medicine, U Florida
Sanjay Munireddy, Thoracic Surgeon, Hopkins
Scott Fahrger, Radiology, USF
Dana Cruite, USF

Undergraduate Trainees

USC

Virgie Blackmun
Eun Yang (PhD)
Vas Subramanian (MD)
Christie Flores (MD)
Cissy Young
Gene Mazzella
Brian Knapp
Marie Nagaya

USF

David Yurek
Irene Saad
Mary Mercer (MD)
Lisa Roth
Nedda Jacques
Karen Conner
Charlotte O'Leary (MD)
Richard Peacock
David Wilson (MD)
Jennifer Jackson
Sanjay Iyer
Jeri Mason (MD)
Jessica Maloney (MD)
Victoria Ronan
Clara Kraft (MD)
John Koren
Keisha Clarke
Justin Rizer

High School Student trainees

Curriculum Vitae, David G. Morgan

USC

Marie Alfaro

USF

Devon Altshuler

Stephanie Hon

Behar Shah

Rahil Rojiani

Rameez Rao

COMMITTEE SERVICE at USF (Major service commitment only)

University Committees

Aging Studies PhD Committee (Chair 1993-2000)

Search Committee, Director Institute on Aging (Chair 1995-1996)

Institute on Aging Research Committee (Chair 1996-2003)

Institute on Aging Executive/Governance Committee (Member 1993-2003)

Health Sciences Center Steering Committee (Member 2002-2004)

HSC Research Center on Aging (Coordinator, 2003-2004)

College Committees

Medical Sciences PhD Program Committee (Member 1993-96; Chair 1995-1996)

Appointment Promotions and Tenure Committee (Member 1997-00; Chair 1999-00)

Second Floor Investigators Committee (Chair 1997-present)

Neurosciences Research Work Group (Member, 2003 –2005)

COM Research Committee (Member 2004-2007; Chair 2005-2007)

MD-PhD Program Committee (co-Director, 2004-present)

Signature Program in Neuroscience Research, Director (Basic Research;2007-present))

Health Science Center Research Cabinet, (Member, 2007-2009)

Executive research Committee, College of medicine member (2010-present)

COURSES INSTRUCTED

In addition to the instructional responsibilities listed below, as Chair of the Aging Studies PhD Program at USF (see above), Dr. Morgan authored the proposal for this program which was approved by the Florida Board of Regents (as the first university-wide PhD program in the state).

Instructional Responsibilities

Dr. Morgan lectures in courses offered by the Dept of Molecular Pharmacology and Physiology, University of South Florida College of Medicine. Tampa FL

Lectures topics include

- Analgesics/Anti-inflammatories (Medications for Minor Pain)
- Antipsychotic Drugs (Medications for Schizophrenia)
- Antidepressant Drugs
- Antiparkinsonian Drugs (Medications for Parkinson's disease)
- Anticonvulsant Drugs (Medications for Epilepsy)
- Barbiturates (Central Nervous System Depressants)
- Benzodiazepines (Medications for Anxiety, Sleep Disorders)
- Chemical Neuroanatomy (Anatomy of Neurotransmitter Systems)
- Ethanol (Alcohol)
- General Anesthetics
- Hallucinogens (Drugs of Abuse)
- Hyperlipidemia
- Immunopharmacology
- Local Anesthetics
- Memory Enhancing Drugs (Medications for Alzheimer's Disease)
- Molecular Therapeutics (Gene Therapy, Antibody Therapy, Antisense Oligonucleotides)
- Neurochemistry (General Neurotransmitter Pharmacology)
- Nutrition and the Aging Process
- Opiate Drugs (Medications for Severe Pain)
- Stimulants (Drugs of Abuse)
- Theories of Aging

Courses Include

Medical Pharmacology. Medical Students

Medical Neuroscience. Medical Students (CoDirector 2000; 2001)

Introduction to Geriatric Medicine. Medical Students

Introduction to Clinical Medicine. Medical Students

Nursing Pharmacology. Nurse Practitioner Students

Cellular and Molecular Pharmacology. PhD Students (Director 1993)

The Pharmacology of Physiological Systems. PhD Students (Director 1995; 1997)

Biomedical Aging. PhD Students (Director 1995;1996:1997;1998;1999;2001)

Neuropharmacology. PhD Students

Principles of Pharmacology. Undergraduate Students

Dr. Morgan has also lectured throughout the USA offering 6 hour seminars on

- Aging and Longevity,**
- Advances in Primary Prevention,**
- Aging Brain, Aging Mind**

Curriculum Vitae, David G. Morgan

These courses offered Continuing Education Units for health professionals and are accredited through state professional organizations.